This is a Phase II, 7-day, randomized, double-blind, placebo-controlled study of orally administered ALLN-346 in subjects with hyperuricemia. Study will take place at a clinical pharmacology unit (CPU). The study will have two Parts with Part 1 administering the target dose and subject continuing Part 2 to explore a lower dose response.~The study will evaluate safety, tolerability, pharmacokinetics (lack of absorption) and pharmacodynamics of ALLN-346.
The purpose of this Phase IIa study is to evaluate the safety and tolerability of ALLN-346 in subjects with hyperuricemia.